Carboplatin in BRCA1/2-mutated and triple-negative breast cancer BRCAness subgroups: the TNT Trial-Reference-Cited by-同舟云学术

Carboplatin in BRCA1/2-mutated and triple-negative breast cancer BRCAness subgroups: the TNT Trial

Published:2018-04-30 Issue:5 Volume:24 Page:628-637
ISSN:1078-8956
Container-title:Nature Medicine
language:en
Short-container-title:Nat Med

Author:

Tutt Andrew^ORCID,Tovey Holly,Cheang Maggie Chon U.,Kernaghan Sarah,Kilburn Lucy,Gazinska Patrycja,Owen Julie,Abraham Jacinta,Barrett Sophie,Barrett-Lee Peter,Brown Robert,Chan Stephen,Dowsett Mitchell,Flanagan James M,Fox Lisa,Grigoriadis Anita^ORCID,Gutin Alexander,Harper-Wynne Catherine,Hatton Matthew Q.,Hoadley Katherine A.,Parikh Jyoti,Parker Peter,Perou Charles M.,Roylance Rebecca,Shah Vandna,Shaw Adam,Smith Ian E.,Timms Kirsten M.,Wardley Andrew M.^ORCID,Wilson Gregory,Gillett Cheryl,Lanchbury Jerry S.,Ashworth Alan,Rahman Nazneen,Harries Mark,Ellis Paul,Pinder Sarah E.^ORCID,Bliss Judith M.

Publisher

Springer Science and Business Media LLC

Subject

General Biochemistry, Genetics and Molecular Biology,General Medicine

Link

http://www.nature.com/articles/s41591-018-0009-7.pdf

Reference50 articles.

1. Kassam, F. et al. Survival outcomes for patients with metastatic triple-negative breast cancer: implications for clinical practice and trial design. Clin. Breast Cancer 9, 29–33 (2009).

2. Sørlie, T. et al. Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications. Proc. Natl. Acad. Sci. USA 98, 10869–10874 (2001).

3. Curtis, C. et al. The genomic and transcriptomic architecture of 2,000 breast tumours reveals novel subgroups. Nature 486, 346–352 (2012).

4. Lehmann, B. D. et al. Identification of human triple-negative breast cancer subtypes and preclinical models for selection of targeted therapies. J. Clin. Invest. 121, 2750–2767 (2011).

5. Lehmann, B. D. et al. Refinement of triple-negative breast cancer molecular subtypes: implications for neoadjuvant chemotherapy selection. PLoS One 11, e0157368 (2016).

Cited by 691 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Platinum Chemotherapy After PARP Inhibition in HRR-Deficient Metastatic Castration-Resistant Prostate Cancer;Clinical Genitourinary Cancer;2024-12

2. Parp-inhibitors in the therapeutic landscape of breast cancer patients with BRCA1 and BRCA2 pathogenic germline variants: An Italian consensus paper and critical review;Cancer Treatment Reviews;2024-11

3. Research trends on nanomaterials in triple negative breast cancer (TNBC): a bibliometric analysis from 2010 to 2024;Drug Delivery and Translational Research;2024-09-06

4. BRCA genetic testing and counseling in breast cancer: how do we meet our patients’ needs?;npj Breast Cancer;2024-09-05

5. Molecular mechanisms of Asparagus racemosus willd. and Withania somnifera (L.) Dunal as chemotherapeutic adjuvants for breast cancer treatment;Journal of Ethnopharmacology;2024-09